Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08

AUTHORS

Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee

ABSTRACT

INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. METHODS: The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials.gov, NCT02252224). RESULTS: After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P < 0.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR ≥ 120 ml/min/1.73 m2) showed the largest reduction in glucose level (% change, - 9.5; 95% CI - 6.8 to - 12.3 for HbA1c; P < 0.001). Multivariable logistic regression analysis showed that recent T2D diagnosis and higher HbA1c at baseline in patients who received an add-on regimen of dapagliflozin were statistically significantly associated with a dapagliflozin response (all P < 0.05). CONCLUSIONS: Dapagliflozin provides benefits for glycemic control and body weight. Patients in a relatively early stage of the course of diabetes with renal hyperfiltration might be more suitable for and gain maximal benefit from dapagliflozin treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02252224. FUNDING: AstraZeneca. More... »

PAGES

1689-1701

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0470-9

DOI

http://dx.doi.org/10.1007/s13300-018-0470-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105493306

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29998370


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Keimyung University", 
          "id": "https://www.grid.ac/institutes/grid.412091.f", 
          "name": [
            "Division of Endocrinology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Han", 
        "givenName": "Eugene", 
        "id": "sg:person.01336264313.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336264313.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (South Korea)", 
          "id": "https://www.grid.ac/institutes/grid.467208.f", 
          "name": [
            "AstraZeneca, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Ari", 
        "id": "sg:person.013665771327.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013665771327.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (South Korea)", 
          "id": "https://www.grid.ac/institutes/grid.467208.f", 
          "name": [
            "AstraZeneca, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Sung Jae", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (South Korea)", 
          "id": "https://www.grid.ac/institutes/grid.467208.f", 
          "name": [
            "AstraZeneca, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Je-Yon", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sungkyunkwan University", 
          "id": "https://www.grid.ac/institutes/grid.264381.a", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Jae Hyeon", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Ulsan", 
          "id": "https://www.grid.ac/institutes/grid.267370.7", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Woo Je", 
        "id": "sg:person.01315723420.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315723420.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yonsei University", 
          "id": "https://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Byung-Wan", 
        "id": "sg:person.01260337416.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260337416.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.diabet.2016.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004155951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci72227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005774065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrneph.2012.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009527766", 
          "https://doi.org/10.1038/nrneph.2012.19"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc09-0625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015369189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bdd.1909", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018433935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027808643"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1742-1241.2012.02911.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028041963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028551220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4093/dmj.2016.40.1.62", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033840562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc10-0612", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033860581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2010.01216.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034183175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2010.01216.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034183175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)60407-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037925022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4093/dmj.2014.38.1.35", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038540596"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.2015.1101450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041903939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4093/dmj.2014.38.4.261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042671816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc11-1693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046026233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.ki.5002160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051291750", 
          "https://doi.org/10.1038/sj.ki.5002160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000005155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053074032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000005155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053074032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/er.2010-0029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064285999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2011-2260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064293098"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-150-9-200905050-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073710774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0248-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084036861", 
          "https://doi.org/10.1007/s13300-017-0248-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0248-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084036861", 
          "https://doi.org/10.1007/s13300-017-0248-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2215/cjn.10180916", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084395323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2215/cjn.10180916", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084395323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep45522", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084508670", 
          "https://doi.org/10.1038/srep45522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4093/dmj.2017.41.2.135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084955620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000007165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090317893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/md.0000000000007165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090317893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091372031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13170", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092955996"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08", 
    "datePublishedReg": "2018-08-01", 
    "description": "INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings.\nMETHODS: The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10\u00a0mg/day) were analyzed (ClinicalTrials.gov, NCT02252224).\nRESULTS: After 12\u00a0weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P\u2009<\u20090.001) from 8.1\u2009\u00b1\u20091.3% to 7.5\u2009\u00b1\u20091.2% and from 28.1\u2009\u00b1\u20094.4 to 27.6\u2009\u00b1\u20094.2\u00a0kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P\u2009<\u20090.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR \u2265\u2009120\u00a0ml/min/1.73\u00a0m2) showed the largest reduction in glucose level (% change, -\u20099.5; 95% CI -\u20096.8 to -\u200912.3 for HbA1c; P\u2009<\u20090.001). Multivariable logistic regression analysis showed that recent T2D diagnosis and higher HbA1c at baseline in patients who received an add-on regimen of dapagliflozin were statistically significantly associated with a dapagliflozin response (all P\u2009<\u20090.05).\nCONCLUSIONS: Dapagliflozin provides benefits for glycemic control and body weight. Patients in a relatively early stage of the course of diabetes with renal hyperfiltration might be more suitable for and gain maximal benefit from dapagliflozin treatment.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02252224.\nFUNDING: AstraZeneca.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-018-0470-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea", 
    "pagination": "1689-1701", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e5cdd3591007937f0ab0d2e897aa5dae41797ba1b82531528c3931aa0cc522e2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29998370"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0470-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105493306"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0470-9", 
      "https://app.dimensions.ai/details/publication/pub.1105493306"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000562.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs13300-018-0470-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0470-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0470-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0470-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0470-9'


 

This table displays all metadata directly associated to this object as RDF triples.

208 TRIPLES      21 PREDICATES      57 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0470-9 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4174f090954f4a3bbba9aefd257a99be
4 schema:citation sg:pub.10.1007/s13300-017-0248-5
5 sg:pub.10.1038/nrneph.2012.19
6 sg:pub.10.1038/sj.ki.5002160
7 sg:pub.10.1038/srep45522
8 https://doi.org/10.1002/bdd.1909
9 https://doi.org/10.1016/j.diabet.2016.11.005
10 https://doi.org/10.1016/s0140-6736(10)60407-2
11 https://doi.org/10.1056/nejmoa1504720
12 https://doi.org/10.1097/md.0000000000005155
13 https://doi.org/10.1097/md.0000000000007165
14 https://doi.org/10.1111/dom.12439
15 https://doi.org/10.1111/dom.13101
16 https://doi.org/10.1111/dom.13170
17 https://doi.org/10.1111/j.1463-1326.2010.01216.x
18 https://doi.org/10.1111/j.1742-1241.2012.02911.x
19 https://doi.org/10.1172/jci72227
20 https://doi.org/10.1210/er.2010-0029
21 https://doi.org/10.1210/jc.2011-2260
22 https://doi.org/10.1517/14656566.2015.1101450
23 https://doi.org/10.2215/cjn.10180916
24 https://doi.org/10.2337/dc09-0625
25 https://doi.org/10.2337/dc10-0612
26 https://doi.org/10.2337/dc11-1693
27 https://doi.org/10.4093/dmj.2014.38.1.35
28 https://doi.org/10.4093/dmj.2014.38.4.261
29 https://doi.org/10.4093/dmj.2016.40.1.62
30 https://doi.org/10.4093/dmj.2017.41.2.135
31 https://doi.org/10.7326/0003-4819-150-9-200905050-00006
32 schema:datePublished 2018-08
33 schema:datePublishedReg 2018-08-01
34 schema:description INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. METHODS: The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials.gov, NCT02252224). RESULTS: After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P < 0.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR ≥ 120 ml/min/1.73 m2) showed the largest reduction in glucose level (% change, - 9.5; 95% CI - 6.8 to - 12.3 for HbA1c; P < 0.001). Multivariable logistic regression analysis showed that recent T2D diagnosis and higher HbA1c at baseline in patients who received an add-on regimen of dapagliflozin were statistically significantly associated with a dapagliflozin response (all P < 0.05). CONCLUSIONS: Dapagliflozin provides benefits for glycemic control and body weight. Patients in a relatively early stage of the course of diabetes with renal hyperfiltration might be more suitable for and gain maximal benefit from dapagliflozin treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02252224. FUNDING: AstraZeneca.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N4748cfff21454433b8a398542b32d069
39 Nba772ba9f4c3460daeb9d10edb36d2b2
40 sg:journal.1044057
41 schema:name Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
42 schema:pagination 1689-1701
43 schema:productId N47888eb0ff1a43499d1534e466ac2ea5
44 N6a1f7fc72581443ea1dbc10f7cc27391
45 Nb63185b6dcd143fe852969717048909c
46 Ndf128753b3714290981f14d081e7c392
47 Nff994f998f7044bd9e933cf137795cc6
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105493306
49 https://doi.org/10.1007/s13300-018-0470-9
50 schema:sdDatePublished 2019-04-10T19:16
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N07a4d2f9aab64ba18f11a04e24f50c18
53 schema:url https://link.springer.com/10.1007%2Fs13300-018-0470-9
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N07a4d2f9aab64ba18f11a04e24f50c18 schema:name Springer Nature - SN SciGraph project
58 rdf:type schema:Organization
59 N09ff0e5c451e4ce0b05437eedc83c1ef rdf:first sg:person.013665771327.20
60 rdf:rest Nf21cbdc4c84e40b5a322184e0999934c
61 N4174f090954f4a3bbba9aefd257a99be rdf:first sg:person.01336264313.26
62 rdf:rest N09ff0e5c451e4ce0b05437eedc83c1ef
63 N4748cfff21454433b8a398542b32d069 schema:volumeNumber 9
64 rdf:type schema:PublicationVolume
65 N47888eb0ff1a43499d1534e466ac2ea5 schema:name dimensions_id
66 schema:value pub.1105493306
67 rdf:type schema:PropertyValue
68 N67e813ef3c614f168b43bace48b5d8f4 schema:affiliation https://www.grid.ac/institutes/grid.467208.f
69 schema:familyName Kim
70 schema:givenName Je-Yon
71 rdf:type schema:Person
72 N6a1f7fc72581443ea1dbc10f7cc27391 schema:name pubmed_id
73 schema:value 29998370
74 rdf:type schema:PropertyValue
75 N73afbb546950458b940a93e884bd5bb6 rdf:first sg:person.01315723420.63
76 rdf:rest Nbc5dd13e9f2d4478bc5d838025924daa
77 N7bd3356ead8245ee869b5589859ca844 schema:affiliation https://www.grid.ac/institutes/grid.467208.f
78 schema:familyName Lee
79 schema:givenName Sung Jae
80 rdf:type schema:Person
81 N7c95aca4502449e8aaa67fa1117d869c rdf:first Nd6ef47b305a242ed97a47c49d86eeac8
82 rdf:rest N73afbb546950458b940a93e884bd5bb6
83 Nb63185b6dcd143fe852969717048909c schema:name nlm_unique_id
84 schema:value 101539025
85 rdf:type schema:PropertyValue
86 Nba772ba9f4c3460daeb9d10edb36d2b2 schema:issueNumber 4
87 rdf:type schema:PublicationIssue
88 Nbc5dd13e9f2d4478bc5d838025924daa rdf:first sg:person.01260337416.14
89 rdf:rest rdf:nil
90 Nd5a8ba06e10f4a879b42f55dcfc37e83 rdf:first N67e813ef3c614f168b43bace48b5d8f4
91 rdf:rest N7c95aca4502449e8aaa67fa1117d869c
92 Nd6ef47b305a242ed97a47c49d86eeac8 schema:affiliation https://www.grid.ac/institutes/grid.264381.a
93 schema:familyName Kim
94 schema:givenName Jae Hyeon
95 rdf:type schema:Person
96 Ndf128753b3714290981f14d081e7c392 schema:name doi
97 schema:value 10.1007/s13300-018-0470-9
98 rdf:type schema:PropertyValue
99 Nf21cbdc4c84e40b5a322184e0999934c rdf:first N7bd3356ead8245ee869b5589859ca844
100 rdf:rest Nd5a8ba06e10f4a879b42f55dcfc37e83
101 Nff994f998f7044bd9e933cf137795cc6 schema:name readcube_id
102 schema:value e5cdd3591007937f0ab0d2e897aa5dae41797ba1b82531528c3931aa0cc522e2
103 rdf:type schema:PropertyValue
104 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
105 schema:name Medical and Health Sciences
106 rdf:type schema:DefinedTerm
107 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
108 schema:name Clinical Sciences
109 rdf:type schema:DefinedTerm
110 sg:journal.1044057 schema:issn 1869-6953
111 1869-6961
112 schema:name Diabetes Therapy
113 rdf:type schema:Periodical
114 sg:person.01260337416.14 schema:affiliation https://www.grid.ac/institutes/grid.15444.30
115 schema:familyName Lee
116 schema:givenName Byung-Wan
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260337416.14
118 rdf:type schema:Person
119 sg:person.01315723420.63 schema:affiliation https://www.grid.ac/institutes/grid.267370.7
120 schema:familyName Lee
121 schema:givenName Woo Je
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315723420.63
123 rdf:type schema:Person
124 sg:person.01336264313.26 schema:affiliation https://www.grid.ac/institutes/grid.412091.f
125 schema:familyName Han
126 schema:givenName Eugene
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336264313.26
128 rdf:type schema:Person
129 sg:person.013665771327.20 schema:affiliation https://www.grid.ac/institutes/grid.467208.f
130 schema:familyName Kim
131 schema:givenName Ari
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013665771327.20
133 rdf:type schema:Person
134 sg:pub.10.1007/s13300-017-0248-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084036861
135 https://doi.org/10.1007/s13300-017-0248-5
136 rdf:type schema:CreativeWork
137 sg:pub.10.1038/nrneph.2012.19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009527766
138 https://doi.org/10.1038/nrneph.2012.19
139 rdf:type schema:CreativeWork
140 sg:pub.10.1038/sj.ki.5002160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051291750
141 https://doi.org/10.1038/sj.ki.5002160
142 rdf:type schema:CreativeWork
143 sg:pub.10.1038/srep45522 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084508670
144 https://doi.org/10.1038/srep45522
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1002/bdd.1909 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018433935
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1016/j.diabet.2016.11.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004155951
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/s0140-6736(10)60407-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037925022
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1056/nejmoa1504720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027808643
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1097/md.0000000000005155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053074032
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1097/md.0000000000007165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090317893
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1111/dom.12439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028551220
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1111/dom.13101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091372031
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1111/dom.13170 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092955996
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1111/j.1463-1326.2010.01216.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034183175
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1111/j.1742-1241.2012.02911.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028041963
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1172/jci72227 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005774065
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1210/er.2010-0029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064285999
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1210/jc.2011-2260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064293098
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1517/14656566.2015.1101450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041903939
175 rdf:type schema:CreativeWork
176 https://doi.org/10.2215/cjn.10180916 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084395323
177 rdf:type schema:CreativeWork
178 https://doi.org/10.2337/dc09-0625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015369189
179 rdf:type schema:CreativeWork
180 https://doi.org/10.2337/dc10-0612 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033860581
181 rdf:type schema:CreativeWork
182 https://doi.org/10.2337/dc11-1693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046026233
183 rdf:type schema:CreativeWork
184 https://doi.org/10.4093/dmj.2014.38.1.35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038540596
185 rdf:type schema:CreativeWork
186 https://doi.org/10.4093/dmj.2014.38.4.261 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042671816
187 rdf:type schema:CreativeWork
188 https://doi.org/10.4093/dmj.2016.40.1.62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033840562
189 rdf:type schema:CreativeWork
190 https://doi.org/10.4093/dmj.2017.41.2.135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084955620
191 rdf:type schema:CreativeWork
192 https://doi.org/10.7326/0003-4819-150-9-200905050-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073710774
193 rdf:type schema:CreativeWork
194 https://www.grid.ac/institutes/grid.15444.30 schema:alternateName Yonsei University
195 schema:name Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.264381.a schema:alternateName Sungkyunkwan University
198 schema:name Division of Endocrinology and Metabolism, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.267370.7 schema:alternateName University of Ulsan
201 schema:name Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.412091.f schema:alternateName Keimyung University
204 schema:name Division of Endocrinology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.467208.f schema:alternateName AstraZeneca (South Korea)
207 schema:name AstraZeneca, Seoul, Korea
208 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...